Artiva Biotherapeutics, Inc. (ARTV)
NASDAQ: ARTV · Real-Time Price · USD
11.19
+0.06 (0.54%)
At close: Sep 4, 2026, 4:00 PM EDT
11.30
+0.11 (0.98%)
After-hours: Sep 4, 2026, 7:45 PM EDT
Artiva Biotherapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
115
Market Cap
547.08M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 251.00K | -33.24M | -99.25% |
| Dec 31, 2023 | 33.49M | 28.56M | 579.21% |
| Dec 31, 2022 | 4.93M | 2.93M | 146.30% |
| Dec 31, 2021 | 2.00M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| REGENXBIO | 174.48M |
| ARS Pharmaceuticals | 116.93M |
| Scribe Therapeutics | 36.28M |
| Prelude Therapeutics | 22.42M |
| Capricor Therapeutics | 11.13M |
| Ovid Therapeutics | 1.58M |
| Entera Bio | 42.00K |
ARTV News
- 3 days ago - Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September - GlobeNewsWire
- 4 weeks ago - Artiva Biotherapeutics files $400M mixed securities shelf - TheFly
- 4 weeks ago - Artiva Biotherapeutics reports Q2 EPS (63c), consensus (64c) - TheFly
- 4 weeks ago - Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewsWire
- 4 weeks ago - Artiva Biotherapeutics Registration statement: Registration filing - Filings
- 4 weeks ago - Artiva Biotherapeutics Quarterly report: Q2 2026 - Filings
- 4 weeks ago - Artiva Biotherapeutics Earnings release: Q2 2026 - Filings
- 4 weeks ago - Artiva Biotherapeutics Proxy statement: Proxy filing - Filings